APPENDIX 12: INTERVENTIONS FOR ADULTS (NETWORK META-ANALYSIS) – STUDY CHARACTERISTICS

Pharmacological interventions 5
Anticonvulsants 5
Gabapentin 5
Levetiracetam 5
Pregabalin 5
Benzodiazepines 6
Alprazolam 6
Clonazepam 6
Monoamine oxidase inhibitors (MAOIs) 7
Moclobemide 7
Phenelzine 8
Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) 9
Citalopram 9
Escitalopram 10
Fluoxetine 10
Fluvoxamine 11
Paroxetine 11
Sertraline 13
Venlafaxine 13
Noradrenaline and selective serotonin antagonists 14
Mirtazapine 14
Psychological interventions 15
Individual cognitive behavioural therapy (CBT) 15
CBT 15
Cognitive therapy (CT) 16
CT, shortened sessions 17
Group CBT 19
CBT (Heimberg) 19
CBT 21
CBT, enhanced 24

Exercise 24
Exercise promotion 24
Exposure in vivo and social skills training 24
Exposure in vivo 24
Social skills training 26
Short-term psychodynamic psychotherapy 26
Self-help without support 27
Book without support 27
Internet without support 29
Self-help with support 29
Book with support 29
Internet with support 30
Other psychological interventions 32
Interpersonal psychotherapy 32
Mindfulness training 33
Supportive therapy 34
Combined psychological and pharmacological interventions 35
Group CBT with fluoxetine 35
Group CBT with phenelzine 35
Group CBT with moclobemide 36
Paroxetine with clonazepam 36
Psychodynamic psychotherapy with clonazepam 36

Key to table headings:

Study	Study identifier; references for the studies can be found in the guideline
Country	Three letter abbreviations (see below) for all countries from which participants were recruited.
Interview	If a structured interview was used, the name of the interview and the diagnostic criteria used.
Age	Mean age of participants.
% Female	Percentage of participants enrolled who were female.
% White	Percentage of participants enrolled who described themselves as white/'Caucasian'.
% Med	Percentage of participants taking medication (for example, an SSRI or benzodiazepine) at baseline. Normally these participants were on a stable dose and agreed not to change their dose during the trial.
N Rand	Number of participants randomised to each group.
N Post	Number of participants who completed assessment at post-treatment.
Group	Name of each group included in the trial.
Dose	For each group, the amount of medication or psychological intervention received. For medication, milligrams per dose (average where possible, otherwise endpoint). For psychological interventions, hours per dose.
Freq	Number of doses per week.
Dur	Number of weeks of intervention. Dose x Freq X Dur = Total amount of medication or psychological intervention received.
Funder	Name of the funder (for example, pharmaceutical company, agency).

Abbreviations

ADIS	Anxiety Disorders Interview Schedule
AUS	Australia
AUT	Austria
BEL	Belgium
BRA	Brazil
CAN	Canada
CBT	cognitive behavioural therapy
CHI	China
CIDI	Composite International Diagnostic Interview
CT	cognitive therapy
CZE	Czech Republic
DEN	Denmark
DSM (-III, -IV, -R)	*Diagnostic and Statistical Manual of Mental Disorders* (3rd edition, 4th edition, Revision)
ESP	Spain
FIN	Finland
FRA	France
GER	Germany
GBR	Great Britain

IRL	Ireland
ISL	Iceland
ISR	Israel
JPN	Japan
KOR	Korea
MINI	Mini International Neuropsychiatric Interview
N/A	not applicable
NCCAM	National Center for Complementary and Alternative Medicine
NED	Netherlands
NIH	National Institutes of Health
NIMH	National Institute of Mental Health
NK_1A	neurokinin-1 antagonist
NOR	Norway
NR	not reported
NRI	noradrenaline reuptake inhibitor
RSA	South Africa
SCID	Structured Clinical Interview for DSM Disorders
SNRI	serotonin and noradrenaline reuptake inhibitor
SSRI	selective serotonin reuptake inhibitor
SWE	Sweden
SWZ	Switzerland
TUR	Turkey
USA	United States of America

PHARMACOLOGICAL INTERVENTIONS

See Chapter 6, Section 6.6 of the guideline.

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
Anticonvulsants													
Gabapentin													
PANDE1999	USA	Clinical interview (DSM-IV)	36	43%	94%	0%	35	35	Pill placebo	N/A	21	14	Parke-Davis Pharmaceutical Research Division of Warner-Lambert (now Pfizer Global Research and Development, Ann Arbor Laboratories).
							34	34	Gabapentin	NR	21	14	
Levetiracetam													
ZHANG2005	USA	MINI (DSM-IV)	38	53%	74%	0%	0	7	Pill placebo	N/A	14	7	UCB Pharma.
							0	9	Levetira-cetam	1139.5	14	7	
Pregabalin													
FELTNER2011	USA	MINI (DSM-IV)	35	41%	79%	0%	82	82	Pill placebo	N/A	21	11	Pfizer.
							82	82	Pregabalin (600 mg)	200	21	11	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
PANDE2004	USA	SCID(DSM-IV)	38	42%	81%	0%	46	46	Pill placebo	N/A	21	10	Parke-Davis Pharmaceutical Research Division of Warner-Lambert (now Pfizer Global Research and Development, Ann Arbor Laboratories).
							47	47	Pregabalin (600 mg)	200	21	10	
							42	42	Pregabalin (150 mg)	50	21	10	
PFIZER2007	BEL; GBR; ISR; NED; SWZ; RSA; USA	MINI (DSM-IV)	37	45%	81%	NR	97	79	Pill placebo	N/A	14	11	Pfizer.
							95	70	Pregabalin (400 mg)	200	14	11	
							95	76	Paroxetine (20 mg)	20	7	11	
							87	71	Pregabalin (200 mg)	100	14	11	
Benzodiazepines													
Alprazolam													
GELERNTER 1991	USA	ADIS (DSM-III)	37	63%	91%	0%	15	15	Pill placebo	N/A	28	12	NIMH (Mental Health Epidemiology grant T32MH14235 from NIMH).
							15	12	Alprazolam	1.05	28	12	
							15	13	Phenelzine	13.75	28	12	
							20	17	CBT (Heimberg), group	2	1	12	
Clonazepam													
DAVIDSON 1993	USA	SCID (DSM-III-R)	37	43%	99%	0%	36	33	Pill placebo	N/A	14	10	None acknowledged.
							39	37	Clonazepam	1.2	14	10	
KNIJNIK2008	BRA	MINI (DSM-IV)	33	61%	NR	0%	29	28	Clonazepam	0.74	14	12	None acknowledged.
							29	29	Psychody-	1.5	1	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									namic psychother-apy				
									Clonazepam	0.645	14	12	
MUNJACK1990	USA	SCID (DSM-III-R)	33	75%	80%	0%	11	10	No treatment	N/A	N/A	8	Roche.
							12	10	Clonazepam	2.75	7	8	
OTTO2000	USA	SCID (DSM-III-R)	40	40%	NR	0%	25	25	Clonazepam	NR	14	12	Roche.
							20	20	CBT (Heimberg), group	2.5	1	12	
Monoamine oxidase inhibitors (MAOIs)													
Moclobemide													
BURROWS1997	AUS; AUT; BEL; BRA; CAN; FRA; GER; GBR; ISL; NED; SWE; SWZ	SCID (DSM-IV)	36	43%	NR	0%	0	194	Pill placebo	N/A	7	12	Hoffmann-La Roche.
							0	193	Moclobemide	600	7	12	
							NR	191	Moclobemide	300	7	12	
OOSTERBAAN 2001	NED	SCID (DSM-III-R)	37	42%	NR	0%	27	19	Pill placebo	N/A	7	15	Hoffmann-La Roche.
							27	24	Moclobemide	589	7	15	
							28	24	CBT, individual	0.75	1	15	
PRASKO2003	CZE	NR	28	52%	NR	NR	0	20	Moclobemide	NR	NR	26	MSMT CR 1M0517.
							0	24	CBT, group	NR	NR	26	
							NR	22	Pill placebo CBT, group	N/A NR	NR NR	26 26	
									Moclobemide	NR	NR	26	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
SCHNEIER1998	USA	SCID (DSM-III-R)	35	40%	80%	0%	37	37	Pill placebo	N/A	14	8	NIMH (5 R29 MH 47831-04).
							40	40	Moclobemide	364	14	8	
STEIN2002a	RSA	SCID (DSM-IV)	34	47%	NR	0%	193	189	Pill placebo	N/A	7	12	Hoffmann-La Roche.
							191	188	Moclobemide	315	14	12	
VERSIANI1992	BRA	SCID (DSM-III-R)	0	NR	NR	0%	0	26	Pill placebo	N/A	7	8	None acknowledged.
							0	26	Moclobemide	580.7	7	8	
							NR	26	Phenelzine	67.5	7	8	
Phenelzine													
BLANCO2010	USA	Clinical interview (DSM-IV)	32	41%	48%	0%	39	27	Pill placebo	N/A	7	12	NIMH (DA023200; MH44119; MH57148); New York State Psychiatric Institute (Drs Blanco, Schneier, Campeas and Liebowitz and Ms Vermes); General Clinical Research Center grant RR00349 from the National Center for Research Resources, National Institutes of Health (NIH), to Temple University.
							45	35	Phenelzine	65.9	7	12	
							40	34	CBT (Heimberg), group	2.5	1	12	
							42	32	CBT (Heimberg), group	2.5	1	12	
									Phenelzine	62	7	12	
GELERNTER 1991	USA	ADIS (DSM-III)	37	63%	91%	0%	15	15	Pill placebo	N/A	28	12	NIMH (Mental Health Epidemiology
							15	12	Alprazolam	1.05	28	12	
							15	13	Phenelzine	13.75	28	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
							20	17	CBT (Heimberg), group	2	1	12	grant T32MH14235 from NIMH).
HEIMBERG 1998	USA	SCID (DSM-III-R)	35	50%	NR	0%	33	26	Psychological placebo	NR	1	12	NIMH.
							33	27	Pill placebo	N/A	7	12	
							31	26	Phenelzine	NR	7	12	
							36	28	CBT (Heimberg), group	2.5	1	12	
LIEBOWITZ 1990	USA	Clinical interview (DSM-III)	34	31%	NR	0%	28	26	Pill placebo	N/A	7	8	NIMH.
							28	23	Beta-antagonist-atenolol	97.6	7	8	
							29	25	Phenelzine	75.7	7	8	
VERSIANI1992	BRA	SCID(DSM-III- R)	0	NR	NR	0%	0	26	Pill placebo	N/A	7	8	None acknowledged.
							0	26	Moclobemide	580.7	7	8	
							NR	26	Phenelzine	67.5	7	8	
Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs)													
Citalopram													
FURMARK2002	SWE	SCID (DSM-IV)	35	44%	100%	0%	6	6	Waitlist	N/A	N/A	9	Swedish Council for Research in Humanities and Social Sciences; Bank of Sweden Tercentenary Foundation; Stockholm and Uppsala University; Swedish Brain Foundation.
							6	6	Citalopram	40	7	9	
							6	6	CBT, group	3	0.9	9	
FURMARK2005	SWE	SCID (DSM-IV)	32	53%	NR	NR	12	12	Pill placebo	N/A	7	6	GlaxoSmith-Kline.
							12	12	NK_1A	5	7	6	
							12	12	Citalopram	40	7	6	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
Escitalopram													
KASPER2005	AUT; CAN; DEN; FIN; GBR; GER; NOR; RSA	MINI (DSM-IV)	38	45%	NR	0%	177	176	Pill placebo	N/A	7	12	Lundbeck.
							181	177	Escitalopram	17.6	7	12	
LADER2004	Multiple	MINI (DSM-IV)	37	53%	99%	0%	166	164	Pill placebo	N/A	7	24	Lundbeck.
							170	162	Escitalopram	20	7	24	
							167	162	Escitalopram (10 mg)	10	7	24	
							167	166	Escitalopram (5 mg)	5	7	24	
							169	166	Paroxetine (20 mg)	20	7	24	
Fluoxetine													
CLARK2003	GBR	SCID (DSM-IV)	33	52%	NR	0%	20	20	Exposure instructions	0.6	1	16	Wellcome Trust.
									Pill placebo	N/A	7	16	
							20	20	Exposure instructions	0.6	1	16	
									Fluoxetine	60	7	16	
							20	20	CT (Clark and Wells), individual	1.25	1	16	
DAVIDSON 2004b	USA	SCID (DSM-IV)	37	46%	78%	0%	60	60	Pill placebo	N/A	7	14	NIMH.
							57	57	Fluoxetine	43.6	7	14	
							60	60	CBT, group	1	1	14	
							59	59	CBT, group	1	1	14	
									Pill placebo	N/A	7	14	
							59	59	CBT, group	1	1	14	
									Fluoxetine	47.3	7	14	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
KOBAK2002	USA	SCID (DSM-IV)	39	58%	NR	NR	30	30	Pill placebo	N/A	7	14	Eli Lilly.
							30	30	Fluoxetine	50	7	14	
Fluvoxamine													
ASAKURA2007	JPN	Clinical interview (DSM-IV)	39	32%	NR	NR	89	89	Pill placebo	N/A	7	10	Solvay and Meiji Seika Kaisha.
							182	176	Fluvoxamine	225	7	10	
DAVIDSON 2004a	USA	SCID (DSM-IV)	37	36%	78%	0%	140	126	Pill placebo	N/A	7	12	Solvay.
							139	121	Fluvoxamine	174	7	12	
STEIN1999	USA	SCID (DSM-IV)	39	36%	NR	0%	44	44	Pill placebo	N/A	7	12	Pharmacia; Upjohn.
							48	42	Fluvoxamine	202	7	12	
VAN-VLIET 1994	NED	Clinical Interview (DSM-III-R)	35	57%	NR	0%	14	13	Pill placebo	N/A	7	12	None acknowledged.
							16	15	Fluvoxamine	150	7	12	
WESTENBERG 2004	FRA; GBR; GER; IRL; NED; RSA; USA	SCID (DSM-IV)	38	52%	NR	0%	151	148	Pill placebo	N/A	7	12	Solvay.
							149	146	Fluvoxamine	209	7	12	
Paroxetine													
ALLGULAN-DER1999	SWE	Clinical interview (DSM-IV)	39	NR	NR	0	48	48	Pill placebo	N/A	7	12	Novo Nodisk Pharma, Sweden.
							48	44	Paroxetine	NR	7	12	
ALLGULAN-DER2004	FRA; FIN; NOR; SWE; USA	MINI (DSM-IV)	39	53%	NR	NR	146	132	Pill placebo	N/A	7	12	Wyeth.
							144	128	Paroxetine (40 mg)	42.4	7	12	
							144	129	Venlafaxine (>75 mg/day)	192.4	7	12	
BALDWIN1999	BEL; ESP; FRA;	MINI (DSM-IV)	36	54%	89%	0%	151	151	Pill placebo	N/A	7	12	SmithKline Beecham.
							139	139	Paroxetine	34.7	7	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
	GBR; GER; IRL; RSA												
GSK2006	JPN	NR	37	52%	0%	NR	133	130	Pill placebo	N/A	7	12	GlaxoSmith-Kline.
							132	132	Paroxetine (20 mg)	20	7	12	
							135	133	Paroxetine (40 mg)	40	7	12	
LADER2004	Multiple	MINI (DSM-IV)	37	53%	99%	0%	166	164	Pill placebo	N/A	7	24	Lundbeck.
							170	162	Escitalopram	20	7	24	
							167	162	Escitalopram (10 mg)	10	7	24	
							167	166	Escitalopram (5 mg)	5	7	24	
							169	166	Paroxetine (20 mg)	20	7	24	
LEPOLA2004	Europe; RSA	MINI (DSM-IV)	39	50%	94%	0%	186	184	Pill placebo	N/A	7	12	GlaxoSmith-Kline.
							189	186	Paroxetine	32.3	7	12	
LIEBOWITZ 2002	CAN; USA	SCID (DSM-IV)	37	41%	82%	NR	95	92	Pill placebo	N/A	7	12	SmithKline Beecham.
							97	89	Paroxetine (20 mg)	20	7	12	
							95	88	Paroxetine (40 mg)	40	7	12	
							97	91	Paroxetine (60 mg)	60	7	12	
LIEBOWITZ 2005b	USA	MINI (DSM-IV)	36	46%	71%	0%	147	144	Pill placebo	N/A	7	12	Wyeth.
							147	136	Paroxetine (40 mg)	46	7	12	
							146	133	Venlafaxine (>75 mg/day)	201.7	7	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
PFIZER2007	BEL; GBR; ISR; NED; SWZ; RSA; USA	MINI (DSM-IV)	37	45%	81%	NR	97	79	Pill placebo	N/A	14	11	Pfizer.
							95	70	Pregabalin (400 mg)	200	14	11	
							95	76	Paroxetine (20 mg)	20	7	11	
							87	71	Pregabalin (200 mg)	100	14	11	
SEEDAT2004	USA	SCID (DSM-IV)	31	21%	NR	0%	14	14	Paroxetine	38.9	1	10	GlaxoSmith-Kline.
									Pill placebo	N/A	14	10	
							14	14	Paroxetine	40	1	10	
									Clonazepam	1	14	10	
STEIN1998	CAN; USA	SCID (DSM-IV)	36	53%	53%	0%	93	92	Pill placebo	N/A	7	12	SmithKline Beecham.
							94	90	Paroxetine	36.6	7	12	
Sertraline													
BLOMHOFF 2001	NOR; SWE	Clinical interview (DSM-IV)	40	60%	NR	NR	95	88	Pill placebo	N/A	7	24	Pfizer.
							98	91	Exposure instructions	0.3	0.7	12	
									Pill placebo	N/A	7	24	
							96	87	Sertraline	120.1	7	24	
							98	88	Exposure instructions	0.3	0.7	12	
									Sertraline	120.1	7	24	
LIEBOWITZ 2003	USA	SCID (DSM-IV)	35	40%	72%	0%	204	196	Pill placebo	N/A	7	12	Pfizer.
							211	205	Sertraline	158.8	7	12	
VAN-AMERIN-GEN2001	CAN	SCID (DSM-IV)	36	40%	93%	0%	69	69	Pill placebo	N/A	7	20	Pfizer.
							135	134	Sertraline	146.7	7	20	
Venlafaxine													
ALLGULAN-DER2004	FRA; FIN; NOR; SWE; USA	MINI (DSM-IV)	39	53%	NR	NR	146	132	Pill placebo	N/A	7	12	Wyeth.
							144	128	Paroxetine (40 mg)	42.4	7	12	
							144	129	Venlafaxine (>75 mg/day)	192.4	7	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
LIEBOWITZ 2005a	USA	MINI (DSM-IV)	35	45%	80%	NR	140	133	Pill placebo	N/A	7	12	Wyeth.
							139	138	Venlafaxine (>75 mg/day)	165	7	12	
LIEBOWITZ 2005b	USA	MINI (DSM-IV)	36	46%	71%	0%	147	144	Pill placebo	N/A	7	12	Wyeth.
							147	136	Paroxetine (40 mg)	46	7	12	
							146	133	Venlafaxine (>75 mg/day)	201.7	7	12	
RICKELS2004	USA	MINI (DSM-IV)	41	43%	97%	0%	0	135	Pill placebo	N/A	7	12	None acknowledged.
							0	126	Venlafaxine (>75 mg/day)	178	7	12	
STEIN2005	USA	MINI (DSM-IV)	37	42%	89%	0%	134	126	Pill placebo	N/A	7	28	Wyeth.
							131	119	Venlafaxine (<75 mg/day)	72.2	7	28	
							130	119	Venlafaxine (>75 mg/day)	213.7	7	28	
Noradrenaline and selective serotonin antagonists													
Mirtazapine													
SCHUTTERS2010	NED	MINI (DSM-IV)	39	57%	NR	0%	30	30	Pill placebo	N/A	7	12	Organon.
							30	30	Mirtazapine	45	7	12	

PSYCHOLOGICAL INTERVENTIONS

See Chapter 6, Section 6.7 of the guideline.

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
Individual cognitive behavioural therapy (CBT)													
CBT (Heimberg)													
GOLDIN2012	USA	ADIS (DSM-IV)	33	46%	57%	0%	37	37	Waitlist	N/A	N/A	16	NIMH (R01 MH076074).
							38	38	CBT (Heimberg), individual	1	1	16	
LEDLEY2009	USA	ADIS (DSM-IV)	35	58%	79%	26%	22	19	Waitlist	0.25	0.5	20	None acknow-ledged.
							16	15	CBT (Heimberg), individual	1.03	1	20	
CBT													
COTTRAUX2000	FRA	Clinical interview (DSM-IV)	34	59%	NR	0%	28	28	Supportive therapy	30	0.5	12	French Ministry of Health (PHRC 94020, Hospices Civils de Lyon).
							27	27	CBT, individual	1.7	1.2	12	
EMMELKAMP 2006	NED	SCID (DSM-IV)	34	52%	NR	NR	18	16	Waitlist	N/A	N/A	20	GGz Groningen; Mental Health Research Foundation VCVGZ
							23	22	Psycho-dynamic psychotherapy	0.75	1	20	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
													(Stichting tot Steun, Bennekom).
HERBERT2004	USA	SCID(DSM-IV)	34	44%	77%	NR	15	15	CBT, individual	1	1	12	NIMH (R01 MH052232).
							19	19	CBT, individual (18weeks)	1	0.7	18	
OOSTERBAAN 2001	NED	SCID (DSM-III-R)	37	42%	NR	0%	27	19	Pill placebo	N/A	7	15	Hoffmann-La Roche.
							27	24	Moclobemide	589	7	15	
							28	24	CBT, individual	0.75	1	15	
PRASKO2003	CZE	NR	28	52%	NR	NR	0	20	Moclobemide	NR	NR	26	MSMT CR 1M0517.
							0	24	CBT, group	NR	NR	26	
ROBILLARD2010	CAN	Clinical interview (DSM-IV)	35	71%	NR	NR	15	15	Waitlist	N/A	N/A	16	None acknow-ledged.
							16	16	CBT, individual	NR	NR	16	
							14	14	CBT, individual (virtual reality exposure)	NR	NR	16	
Cognitive therapy (CT)													
CLARK2003	GBR	SCID(DSM-IV)	33	52%	NR	0%	20	20	Exposure instructions	0.58	1	16	Wellcome Trust.
									Pill placebo	N/A	7	16	
							20	20	Exposure instructions	0.58	1	16	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									Fluoxetine	60	7	16	
							20	20	CT (Clark and Wells), individual	1.25	1	16	
CLARK2006	GBR	ADIS (DSM-IV)	32	44%	89%	28%	20	20	Waitlist	N/A	N/A	14	Wellcome Trust (037158/Z/96/DG).
							21	21	Exposure *in vivo*	1.5	1	14	
							21	21	CT (Clark and Wells), individual	1.5	1	14	
CLARK2012	GBR	ADIS (DSM-IV)	33	NR	NR	28%	27	27	Waitlist	N/A	N/A	14	None acknow-ledged.
							28	28	CT (Clark and Wells), individual	1.5	1	14	
							27	27	CT (Clark and Wells), individual (with self-study)	1.5	0.5	14	
							21	18	CBT, individual	0.75	1	20	
CT, shortened sessions													
LEICHSENRING 2012	GER	SCID (DSM-IV)	35	55%	NR	0%	79	79	Waitlist	N/A	N/A	0	German Federal Ministry of Education and Research (BMBF 01GV0607).
							207	207	Psycho-dynamic psychotherapy	1	1	26	
MORTBERG2007	SWE	SCID(DSM-IV)	35	63%	NR	NR	33	33	Treatment as usual	N/A	N/A	3	Boethius Foundation; Soderstrom-Konigska Foundation; The Organon Foundation;
							35	35	CBT, group	5.13	2.67	3	
							32	32	CT (Clark and Wells), individual shortened	1	1	17	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									sessions				FOU (The Research and Developmen t Centre) of Stockholm County Council.
									Pill placebo	N/A	NR	26	
							NR	22	CBT, individual	NR	NR	26	
									Moclobemide	NR	NR	26	
STANGIER2003	GER	SCID (DSM-IV)	39	49%	NR	5%	37	21	Waitlist	N/A	N/A	43	None acknow-ledged.
							32	22	CBT, group	2	1	15	
							26	22	CT (Clark and Wells), individual shortened sessions	1	1	15	
STANGIER2011	GER	SCID (DSM-IV)	36	56%	NR	0%	41	39	Waitlist	0.83	0.8	20	German Research Foundation, Deutsche Forschungs-gemeinschaft (grants STA 512/2-1/2); Wellcome Trust (069777); National Institute for Health Research Biomedical Research Centre at the South London and Maudsley NHS
							38	36	Interpersonal psychotherapy	0.83	0.8	20	
							38	36	CT (Clark and Wells), individual shortened sessions	0.83	0.8	20	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
													Foundation Trust and King's College London.
Group CBT													
CBT (Heimberg)													
BLANCO2010	USA	Clinical interview (DSM-IV)	32	41%	48%	0%	39	27	Pill placebo	N/A	7	12	NIMH (DA023200; MH44119; MH57148); New York State Psychiatric Institute (Drs Blanco, Schneier, Campeas, and Liebowitz and Ms Vermes); General Clinical Research Center grant RR00349 from the National Center for Research Resources, NIH, to Temple University.
							45	35	Phenelzine	65.9	7	12	
							40	34	CBT group	2.5	1	12	
							42	32	CBT group	2.5	1	12	
									Phenelzine	62	7	12	
GELERNTER	USA	ADIS	37	63%	91%	0%	15	15	Pill placebo	N/A	28	12	NIMH

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
1991		(DSM-III)					15	12	Alprazolam	1.05	28	12	(Mental Health Epidemio-logy grant T32MH14235 from the NIMH).
							15	13	Phenelzine	13.75	28	12	
							20	17	CBT group	2	1	12	
GRUBER2001	GER; USA	ADIS (DSM-III-R)	42	52%	NR	17%	18	17	Waitlist	N/A	N/A	12	Deutscher Akadem-ischer Austausch-dienst (DAAD; German Academic Exchange Service).
							18	14	CBT group	2.5	1	12	
							18	15	CBT group (with self-study)	2.5	0.67	12	
HEDMAN2011	SWE	SCID (DSM-IV)	35	36%	NR	25%	64	64	Self-help (internet) with support	N/A	N/A	15	Stockholm County Council (Nils Lindefors) and the Bror Gadelius Fund (Erik Hedman).
							62	62	CBT group	2.5	1	15	
HEIMBERG1990	USA	ADIS (DSM-III)	30	45%	NR	NR	24	20	Psychological placebo	2	1	12	NIMH.
							25	20	CBT group	2	1	12	
HEIMBERG1998	USA	SCID (DSM-III-R)	35	50%	NR	0%	33	26	Psychological placebo	NR	1	12	NIMH.
							33	27	Pill placebo	N/A	7	12	
							31	26	Phenelzine	NR	7	12	
							36	28	CBT group	2.5	1	12	
HERBERT2005	USA	SCID (DSM-IV)	34	57%	65%	23%	30	30	CBT group	2	1	12	NIMH.
							35	35	CBT group (with social	2	1	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									skills)				
HOPE1995	USA	ADIS (DSM-III-R)	34	50	NR	30%	11	10	Waitlist	N/A	N/A	12	University of Nebraska-Lincoln Research Council Faculty.
							11	10	Exposure (*in vivo*)	2.25	1	12	
							18	13	CBT group	2.25	1	12	
KOSZYCKI2007	CAN	MINI (DSM-IV)	38	53%	NR	28%	26	26	Mindfulness training	2.5	1	8	University (Ottawa) Medical Research Fund.
							27	27	CBT group	2.5	1	12	
OTTO2000	USA	SCID (DSM-III-R)	40	40%	NR	0%	25	25	Clonazepam	NR	14	12	Roche.
							20	20	CBT group	2.5	1	12	
WONG2006	CHI	NR	35	41%	0%	100 %	17	17	Waitlist	N/A	N/A	10	University of Hong Kong (Committee on Research and Conference Grant).
							17	17	CBT group	2.5	1	10	
CBT													
ALDEN2011	CAN	ADIS (DSM-IV)	34	41%	NR	38%	25	23	Waitlist	N/A	N/A	12	Social Sciences and Humanities Council of Canada.
							31	27	CBT (enhanced), group	2	1	12	
ANDREWS2011	AUS	NR	32	41%	NR	NR	23	14	Self-help (internet) with support	0.05	0.75	8	None acknow-ledged.
							14	11	CBT, group	4	1	7	
BJORNSSON 2011	USA	Clinical interview (DSM-IV)	20	47%	89%	0%	0	23	Psychological placebo	2	1	8	None acknow-ledged.
							0	22	CBT, group	2	1	8	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
BORGEAT2009	SWZ	Clinical interview (DSM-IV)	40	53%	NR	NR	15	13	Exposure *in vivo*	2.5	1	8	None acknow-ledged.
							15	14	CBT, group	2.5	1	8	
DAVIDSON 2004b	USA	SCID (DSM-IV)	37	46%	78%	0%	60	60	Pill placebo	N/A	7	14	NIMH.
							57	57	Fluoxetine	43.6	7	14	
							60	60	CBT, group	1	1	14	
							59	59	CBT, group	1	1	14	
									Pill placebo	N/A	7	14	
							59	59	CBT, group	1	1	14	
									Fluoxetine	47.3	7	14	
FURMARK2002	SWE	SCID (DSM-IV)	35	44%	100%	0%	6	6	Waitlist	N/A	N/A	9	Swedish Council for Research in Humanities and Social Sciences; Bank of Sweden Tercentenary Foundation; Stockholm and Uppsala University; Swedish Brain Foundation.
							6	6	Citalopram	40	7	9	
							6	6	CBT, group	3	0.89	9	
MATTICK1988	AUS	Clinical Interview (DSM-III)	37	53%	100%	NR	26	23	Exposure *in vivo*	2	1	6	Australian Government Common-
							25	21	CBT, group	2	1	6	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
													wealth Postgraduate Research Award.
MATTICK1989	AUS	Clinical Interview (DSM-III)	42	53%	NR	NR	10	8	Waitlist	N/A	N/A	6	Australian Government Common-wealth Postgraduate Research Award.
							11	10	Exposure (*in vivo*)	2	1	6	
							11	9	Cognitive restructuring	2	1	6	
							11	10	CBT, group	2	1	6	
MCEVOY2009	AUS	Clinical Interview (DSM-IV)	31	37%	NR	56%	36	30	CBT, group	4	1	7	None acknowled-ged.
							39	30	CBT, group (with attention training)	4	1	7	
MORGAN1999	AUS	Clinical Interview (DSM-III R)	32	47%	NR	47%	16	14	CBT, group	8	3.33	3	None acknowled-ged.
							20	16	CBT, group (with safety behaviours)	8	3.33	3	
MORTBERG2007	SWE	SCID (DSM-IV)	35	63%	NR	NR	33	33	Treatment as usual	N/A	N/A	3	Boethius Foundation; Soderstrom-Konigska Foundation; The Organon Foundation; FOU (The Research and Developmen t Centre) of Stockholm County Council.
							35	35	CBT, group	5.13	2.67	3	
							32	32	CT (Clark and Wells), individual shortened sessions	1	1	17	
PIET2010	DEN	ADIS (DSM-IV)	22	69%	NR	0%	14	14	Mindfulness training	2	1	8	None acknowled-ged.
							12	12	CBT, group	2	1	14	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
RAPEE2009	AUS	ADIS (DSM-IV)	34	52%	NR	27%	58	56	Psychological placebo	2	1	12	National Health and Medical Research Council of Australia.
							66	59	CBT, group	2	1	12	
							71	68	CBT, group (enhanced exposure)	2	1	12	
SALABERRIA 1998	ESP	ADIS (DSM-III R)	31	48%	100%	NR	23	20	Waitlist	0	0	8	University of the Basque Country.
							24	18	Exposure *in vivo*	2.5	1	8	
							24	18	CBT, group	2.5	1	8	
STANGIER2003	GER	SCID (DSM-IV)	39	49%	NR	5%	37	21	Waitlist	N/A	N/A	43	None acknowled-ged.
							32	22	CBT, group	2	1	15	
							26	22	CT (Clark and Wells), individual shortened sessions	1	1	15	
CBT, enhanced													
RAPEE2007	AUS	ADIS (DSM-IV)	36	51	NR	32%	52	52	Waitlist	N/A	N/A	12	None acknowled-ged.
							56	56	Self-help (book) no support	N/A	N/A	12	
							59	59	CBT, group	2	0.83	12	
							57	57	CBT, group (with self-study)	2	0.42	12	
Exercise													
Exercise promotion													
JAZAIERI2012	USA	ADIS (DSM-IV)	34	52%	56%	0%	25	18	Exercise	NR	NR	8	NIMH (MH76074) NCCAM) (AT003644).
							31	24	Mindfulness training	2.5	1	8	
Exposure in vivo and social skills training													
Exposure in vivo													
ANDERSSON 2006	SWE	SCID (DSM-IV)	37	52%	NR	22%	32	32	Waitlist	N/A	N/A	9	Swedish Research
							32	30	Exposure *in*	3	1	2	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									vivo				Council; Soderstrom-Konigska Foundation.
									Self-help (book) no support	N/A	N/A	9	
BORGEAT2009	SWZ	Clinical interview (DSM-IV)	40	53%	NR	NR	15	13	Exposure *in vivo*	2.5	1	8	None acknowled-ged
							15	14	CBT, group	2.5	1	8	
CLARK2006	GBR	ADIS (DSM-IV)	32	44%	89%	28%	20	20	Waitlist	N/A	N/A	14	Wellcome Trust (037158/Z/96/DG).
							21	21	Exposure *in vivo*	1.5	1	14	
							21	21	CT (Clark and Wells), individual	1.5	1	14	
HOPE1995	USA	ADIS (DSM-III-R)	34	50%	NR	30%	11	10	Waitlist	N/A	N/A	12	University of Nebraska-Lincoln Research Council Faculty.
							11	10	Exposure *in vivo*	2.25	1	12	
							18	13	CBT (Heimberg), group	2.25	1	12	
MATTICK1988	AUS	Clinical interview (DSM-III)	37	53%	100%	NR	26	23	Exposure *in vivo*	2	1	6	Australian Government Common-wealth Postgraduate Research Award.
							25	21	CBT, group	2	1	6	
MATTICK1989	AUS	Clinical interview (DSM-III)	42	53%	NR	NR	10	8	Waitlist	N/A	N/A	6	Australian Government Common-wealth Postgraduate Research Award.
							11	10	Exposure *in vivo*	2	1	6	
							11	9	Cognitive Restructuring	2	1	6	
							11	10	CBT, group	2	1	6	
SALABERRIA	ESP	ADIS	31	48%	100%	NR	23	20	Waitlist	0	0	8	University of

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
1998		(DSM-III-R)					24	18	Exposure *in vivo*	2.5	1	8	the Basque Country.
							24	18	CBT, group	2.5	1	8	
SMITS2006	USA	CIDI (DSM-IV)	22	57%	77%	NR	15	15	Psychological placebo	1.25	3	1	Society for a Science of Clinical Psychology
							23	18	Exposure *in vivo*	1.25	3	1	
							20	17	Exposure *in vivo*, audience feedback	1.25	3	1	
							19	18	Exposure *in vivo*, performance feedback	1.25	3	1	
STRAVYNSKI 2000	CAN	ADIS (DSM-IV)	38	58%	NR	NR	32	28	Social skills training	2	1	12	None acknowled-ged.
							36	32	Exposure *in vivo*	2	1	12	
Social skills training													
STRAVYNSKI 2000	CAN	ADIS (DSM-IV)	38	58%	NR	NR	32	28	Social skills training	2	1	12	None acknowled-ged.
							36	32	Exposure *in vivo*	2	1	12	
Short-term psychodynamic psychotherapy													
EMMELKAMP 2006	NED	SCID (DSM-IV)	34	52%	NR	NR	18	16	Waitlist	N/A	N/A	20	GGz Groningen; Mental Health Research Foundation VCVGZ (Stichting tot Steun, Bennekom).
							23	22	Psycho-dynamic psychotherapy	0.75	1	20	
							21	18	CBT, individual	0.75	1	20	
KNIJNIK2004	BRA	MINI (DSM-IV)	33	61%	NR	0%	29	28	Clonazepam	0.74	14	12	Roche; NIH (DA00482;
							29	29	Psychodyna-	1.5	1	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									mic psycho-therapy				DA019606). Fundação de Incentivo à Pesquisa e Eventos (FIPE) at the Hospital de Clínicas de Porto Alegre, Brazil.
									Clonazepam	0.645	14	12	
LEICHSENRING 2012	GER	SCID (DSM-IV)	35	55%	NR	0%	79	79	Waitlist	N/A	N/A	0	German Federal Ministry of Education and Research (BMBF 01GV0607).
							207	207	Psychodyna-mic psycho-therapy	1	1	26	
							209	209	CT (Clark and Wells), individual shortened sessions	1	1	26	
Self-help without support													
Book without support													
CHUNG2008	KOR	ADIS (DSM-IV)	26	40%	NR	NR	18	14	Waitlist	N/A	N/A	6	Korea Science and Engineering Foundation funded by the Korean government (Ministry of Education, Science and Technology) (R01-2008-000-11782-0).
							12	11	Self-help (book) no support	N/A	N/A	6	
							15	13	Self-help (book) with support	N/A	N/A	6	
FURMARK2009a	SWE	SCID (DSM-IV)	36	68%	NR	67%	40	40	Waitlist	N/A	N/A	9	Swedish Research
							40	40	Self-help	N/A	1	9	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									(book) no support				Council. The manual was released as a self-help book for the Swedish market after completion of the study and the authors receive royalties.
							40	40	Self-help (internet) with support	N/A	1	9	
FURMARK2009b	SWE	SCID (DSM-IV)	35	68%	NR	14%	29	29	Self-help (book) no support	N/A	1	9	Swedish Research Council. The manual was released as a self-help book for the Swedish market after completion of the study and the authors receive royalties.
							28	28	Self-help (book) with discussion group	N/A	1	9	
							29	29	Self-help (internet) with support	N/A	1	9	
							29	29	Self-help (internet) with support (applied relaxation)	N/A	1	9	
RAPEE2007	AUS	ADIS (DSM-IV)	36	51%	NR	32%	52	52	Waitlist	N/A	N/A	12	None acknowled-ged.
							56	56	Self-help (book) no support	N/A	N/A	12	
							59	59	CBT, group	2	0.8	12	
							57	57	CBT, group (with self-study)	2	0.4	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
Internet without support													
TITOV2008c	AUS	MINI (DSM-IV-R)	38	61%	NR	22%	35	34	Waitlist	N/A	N/A	10	None acknowled-ged.
							31	30	Self-help (internet) no support	N/A	N/A	10	
							32	31	Self-help (internet) with support	N/A	N/A	10	
TITOV2009b	AUS	MINI (DSM-IV)	41	52%	NR	22%	84	82	Self-help (internet) no support	N/A	N/A	8	None acknowled-ged.
							84	81	Self-help (internet) with support	N/A	N/A	8	
TITOV2010b	AUS	MINI (DSM-IV)	44	47%	NR	16%	56	55	Self-help (internet) no support	N/A	N/A	8	None acknowled-ged.
							57	53	Self-help (internet) no support (with motivational enhancement)	N/A	N/A	8	
Self-help with support													
Book with support													
ABRAMOWITZ 2009	USA	MINI (DSM-IV)	43	76%	100%	57%	10	10	Waitlist	N/A	N/A	8	Mayo Clinic and Mayo Foundation. Grant awarded to Elizabeth Moore.
							11	11	Self-help (book) with support	N/A	N/A	8	
CHUNG2008	KOR	ADIS (DSM-IV)	26	40%	NR	NR	18	14	Waitlist	N/A	N/A	6	Korea Science and Engineering Foundation funded by
							12	11	Self-help (book) no support	N/A	N/A	6	
							15	13	Self-help	N/A	N/A	6	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									(book) with support				the Korean government (Ministry of Education, Science and Technology) (R01-2008-000-11782-0).
Internet with support													
ANDERSSON 2012	SWE	SCID (DSM-IV)	38	60%	NR	14%	102	102	Waitlist	N/A	N/A	9	Swedish Research Council; Linkoping University.
							102	102	Self-help (internet) with support	N/A	N/A	9	
ANDREWS2011	AUS	NR	32	41%	NR	NR	23	14	Self-help (internet) with support	0.05	0.75	8	None acknowled-ged.
							14	11	CBT, group	4	1	7	
BERGER2009	SWZ	SCID (DSM-IV)	29	56%	NR	NR	21	21	Waitlist	N/A	N/A	10	Swiss National Science Foundation (SNF 100011-112345).
							31	31	Self-help (internet) with support	N/A	N/A	10	
CARLBRING 2007	SWE	SCID (DSM-IV-R)	33	62%	NR	NR	30	28	Waitlist	N/A	N/A	8	Swedish Research Council; Soderstrom-Konigska Foundation.
							30	29	Self-help (internet) with support	N/A	N/A	8	
FURMARK2009a	SWE	SCID (DSM-IV)	36	68%	NR	67%	40	40	Waitlist	N/A	N/A	9	Swedish Research Council. The manual was released as a self-help
							40	40	Self-help (book) no support	N/A	1	9	
							40	40	Self-help (internet) with	N/A	1	9	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
									support				book for the Swedish market after completion of the study and the authors receive royalties.
FURMARK2009b	SWE	SCID (DSM-IV)	35	68%	NR	14%	29	29	Self-help (book) no support	N/A	1	9	Swedish Research Council. The manual was released as a self-help book for the Swedish market after completion of the study and the authors receive royalties.
							28	28	Self-help (book) with discussion group	N/A	1	9	
							29	29	Self-help (internet) with support	N/A	1	9	
							29	29	Self-help (internet) with support (applied relaxation)	N/A	1	9	
HEDMAN2011	SWE	SCID (DSM-IV)	35	36%	NR	25%	64	64	Self-help (internet) with support	N/A	N/A	15	Stockholm County Council (Nils Lindefors) and the Bror Gadelius Fund (Erik Hedman).
							62	62	CBT (Heimberg), group	2.5	1	15	
TITOV2008a	AUS	CIDI (DSM-IV-R)	38	59%	NR	30%	55	49	Waitlist	N/A	N/A	10	University of New South Wales (Faculty of
							50	50	Self-help (internet) with support	N/A	N/A	10	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
													Medicine).
TITOV2008b	AUS	CIDI (DSM-IV-R)	37	63%	NR	26%	45	40	Waitlist	N/A	N/A	10	University of New South Wales (Faculty of Medicine).
							43	41	Self-help (internet) with support	N/A	N/A	10	
TITOV2008c	AUS	MINI (DSM-IV-R)	38	61%	NR	22%	35	34	Waitlist	N/A	N/A	10	None acknowled-ged.
							31	30	Self-help (internet) no support	N/A	N/A	10	
							32	31	Self-help (internet) with support	N/A	N/A	10	
TITOV2009a	AUS	MINI (DSM-IV)	39	56%	NR	28%	42	39	Self-help (internet) with support	N/A	N/A	8	None acknowled-ged.
							43	43	Self-help (internet) with support (discussion group)	N/A	N/A	8	
TITOV2009b	AUS	MINI (DSM-IV)	41	52%	NR	22%	84	82	Self-help (internet) no support	N/A	N/A	8	None acknowled-ged.
							84	81	Self-help (internet) with support	N/A	N/A	8	
Other psychological interventions													
Interpersonal psychotherapy													
LIPSITZ2008	USA	Clinical interview (DSM-IV)	35	43%	50%	NR	34	26	Supportive therapy	NR	1	14	NIMH.
							36	26	Interpersonal psychotherapy	NR	1	14	
STANGIER2011	GER	SCID (DSM-IV)	36	56%	NR	0%	41	39	Waitlist	0.83	0.8	20	German Research Foundation,
							38	36	Interpersonal psychotherapy	0.83	0.8	20	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
							38	36	CT (Clark and Wells), individual shortened sessions	0.83	0.8	20	Deutsche Forschungs-gemeinschaft (grants STA 512/2-1/2); Wellcome Trust (069777); National Institute for Health Research Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King's College London.
Mindfulness training													
JAZAIERI2012	USA	ADIS (DSM-IV)	34	52%	56%	0%	25	18	Exercise	NR	NR	8	NIMH (MH76074) NCCAM (AT003644).
							31	24	Mindfulness	2.5	1	8	
KOSZYCKI2007	CAN	MINI (DSM-IV)	38	53%	NR	28%	26	26	Mindfulness	2.5	1	8	University (Ottawa) Medical Research Fund.
							27	27	CBT (Heimberg), group	2.5	1	12	
PIET2010	DEN	ADIS (DSM-IV)	22	69%	NR	0%	14	14	Mindfulness training	2	1	8	None acknowled-

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
							12	12	CBT, group	2	1	14	ged.
Supportive therapy													
COTTRAUX2000	FRA	Clinical interview (DSM-IV)	34	59%	NR	0%	28	28	Supportive therapy	30	0.5	12	French Ministry of Health (PHRC 94020, Hospices Civils de Lyon).
							27	27	CBT, individual	1.7	1.2	12	
LIPSITZ2008	USA	Clinical interview (DSM-IV)	35	43%	50%	NR	34	26	Supportive therapy	NR	1	14	NIMH.
							36	26	Interpersonal psychotherapy	NR	1	14	

COMBINED PSYCHOLOGICAL AND PHARMACOLOGICAL INTERVENTIONS

See Chapter 6, Section 6.8 of the guideline.

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
Group CBT with fluoxetine													
DAVIDSON 2004b	USA	SCID (DSM-IV)	37	0.46	0.78	0	60	60	Pill placebo	N/A	7	14	NIMH.
							57	57	Fluoxetine	43.6	7	14	
							60	60	CBT, group	1	1	14	
							59	59	CBT, group	1	1	14	
									Pill placebo	N/A	7	14	
							59	59	CBT, group	1	1	14	
									Fluoxetine	47.3	7	14	
Group CBT with phenelzine													
BLANCO 2010	USA	Clinical interview (DSM-IV)	32	0.41	0.48	0	39	27	Pill placebo	N/A	7	12	NIMH (DA023200; MH44119; MH57148); New York State Psychiatric Institute (Drs Blanco, Schneier, Campeas, and Liebowitz and Ms Vermes); General Clinical Research Center grant RR00349 from the National Center for Research Resources, NIH, to Temple University.
							45	35	Phenelzine	65.9	7	12	
							40	34	CBT (Heimberg), group	2.5	1	12	
							42	32	CBT (Heimberg), group	2.5	1	12	
									Phenelzine	62	7	12	

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur	Funder
Group CBT with moclobemide													
PRASKO 2003	CZE	NR	28	0.52	NR	NR	0	20	Moclobemide	NR	NR	26	MSMT CR 1M0517.
							0	24	CBT, group	NR	NR	26	
									Pill placebo	N/A	NR	26	
							NR	22	CBT, group	NR	NR	26	
									Moclobemide	NR	NR	26	
Paroxetine with clonazepam													
SEEDAT2004	USA	SCID (DSM-IV)	31	21%	NR	0%	14	14	Paroxetine	38.9	1	10	GlaxoSmith-Kline.
									Pill placebo	N/A	14	10	
							14	14	Paroxetine	40	1	10	
									Clonazepam	1	14	10	
Psychodynamic psychotherapy with clonazepam													
KNIJNIK 2008	BRA	MINI (DSM-IV)	33	0.61	NR	0	29	28	Clonazepam	0.74	14	12	Roche; NIH (DA00482; DA019606). Fundação de Incentivo à Pesquisa e Eventos (FIPE) at the Hospital de Clínicas de Porto Alegre, Brazil.
							29	29	Psychodynamic psychotherapy	1.5	1	12	
									Clonazepam	0.645	14	12	